Low plasma miR-25 expression is a favorite prognosis factor in non-small cell lung cancer.
Circulating microRNAs (miRNAs) are promising biomarkers for the diagnosis and prognosis prediction of cancer. In the study, we aimed to investigate the potential clinical significance of the plasma miR-25 in non-small cell lung carcinoma (NSCLC). We first compared the miRNAs expression pattern between NSCLC tissues and adjacent normal tissues then, bioinformatic analysis of the downstream targets of miR-25 was performed. The diagnostic and prognostic value of the plasma miR-25 in NSCLC was then evaluated. The expression level of miR-25 was increased in NSCLC tissues compared to the adjacent normal tissues. In addition, bioinformatic analysis of the downstream-targeted genes of miR-25 revealed that many gene ontology functions and pathways were associated with cancer progression. The levels of plasma miR-25 were significantly upregulated in NSCLC patients compared to normal controls. In addition, the plasma miR-25 levels were especially higher in NSCLC patients with positive lymph node metastasis, poorly differentiation or advanced clinical stage. Subsequently, we found that the plasma miR-25 expression levels were dramatically decreased in 45 NSCLC patients after receiving surgical treatment. The receiver operating characteristic (ROC) curve analysis indicated that the plasma miR-25 exhibited high diagnostic sensitivity and specificity to discriminate NSCLC cases from healthy subjects. More interestingly, the combination of the plasma miR-25 and carcinoembryonic antigen (CEA) could effectively enhance the accuracy for distinguishing NSCLC patients from normal controls. Moreover, the plasma miR-25 overexpression was closely correlated with aggressive clinical characteristics and poor survival. Finally, the plasma miR-25 was identified as an independent prognostic marker for the overall survival of NSCLC. Collectively, our findings demonstrated that the plasma miR-25 might serve as a novel promising biomarker in the diagnosis and prognosis prediction of NSCLC.